← Leaderboards
Edward G Maliski
Oak Therapeutics, Inc.
$1,383,091
Attributed
$1,383,091
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $892.8K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,383,091 · 3
By mechanism
R44$892,787 · 1
R43$490,304 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Pharmacologic Substance”
- Lauren Miller · Technical Resources International, Inc.$31,120,905
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Mehrinfar Mahzad · Fisher Bioservices, Inc.$18,271,500
- Bambra Stokes · Ppd Development Lp$17,155,112
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Debra Burnin · Sri International$9,413,546
Research focus
Pharmacologic SubstanceSmall Business Innovation Research GrantIn VitroPharmaceutical PreparationsPreparationRattusChildInfantMedicalPersonsPhysical PropertyEncapsulatedPropertyFormulationAdherenceCaregiversBarrier To CareDoseChildhoodIn VivoOralPediatric PatientsDrug KineticsTablets
Grant awards (3)
Oral Dissolvable Strips (ODS) as new pediatric and adult delivery mode of therapy for latent tuberculosis$892,787
R44 · FY2025 · AI · contact PI
Oral Dissolvable Strips (ODS) as new pediatric and adult delivery mode of therapy for latent tuberculosis$273,458
R43 · FY2023 · AI · contact PI
Novel antiretroviral therapy delivery platform for infants and young children: oral dispensable strips (ODS)$216,846
R43 · FY2022 · AI · contact PI